An optical coherence tomography study of a photoactive Pt(iv) prodrug in oesophageal tissue

Huayun Shi1,2,3, Muktesh Mohan4,5, Kanwarpal Singh4,5,6

  • 1Department of Chemistry, University of Warwick Coventry CV4 7AL UK Huayun.Shi@xmu.edu.cn p.j.sadler@warwick.ac.uk.

RSC Advances
|February 3, 2025
PubMed

Insights

Photoactive platinum(IV) complexes show promise for esophageal cancer treatment. Optical coherence tomography (OCT) effectively detected tissue damage from a novel platinum complex (FM190) activated by blue laser light.

Area of Science:

  • Biomedical Optics
  • Cancer Therapeutics
  • Materials Science

Background:

  • Photoactive platinum(IV) complexes demonstrate in vivo anticancer activity against esophageal tumors.
  • Esophageal cancer remains a significant global health challenge.
  • Developing targeted therapies and effective monitoring methods is crucial.

Purpose of the Study:

  • To investigate optical coherence tomography (OCT) as a method for detecting tissue penetration and damage.
  • To evaluate the effects of a photoactivatable platinum(IV) complex, FM190, on esophageal tissue.
  • To assess the combined effect of FM190 and blue laser light on tissue.

Main Methods:

  • Utilized an optical coherence tomography (OCT) system to image swine esophageal tissue.
  • Treated tissue samples with the photoactivatable platinum(IV) complex FM190.
  • Exposed treated tissue to blue laser light (445 nm).
  • Analyzed OCT images for signs of tissue dehydration and changes in refractive index.

Main Results:

  • OCT detected dehydration and refractive index changes in swine esophageal tissue treated with FM190 and blue laser light.
  • Tissue treated with FM190 alone or blue laser light alone showed no significant damage.
  • FM190 requires photoactivation by blue laser light to induce observable tissue changes.

Conclusions:

  • Optical coherence tomography (OCT) is a viable tool for monitoring the effects of photoactivatable anticancer agents in tissues.
  • The platinum(IV) complex FM190, when activated by blue light, causes localized tissue damage.
  • This study highlights a potential strategy for targeted cancer therapy and real-time monitoring.